Yungjin Pharm. Co., Ltd. (003520.KS)
KRW 1989.0
(-2.02%)
KRW 1989.0
(-2.02%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 61.98 Billion KRW | 27.9% |
| 2022 | 48.46 Billion KRW | 22.22% |
| 2021 | 39.65 Billion KRW | -22.91% |
| 2020 | 51.43 Billion KRW | -8.08% |
| 2019 | 55.95 Billion KRW | 16.98% |
| 2018 | 47.83 Billion KRW | 17.56% |
| 2017 | 40.68 Billion KRW | -7.78% |
| 2016 | 44.11 Billion KRW | 33.27% |
| 2015 | 33.1 Billion KRW | 7.15% |
| 2014 | 30.89 Billion KRW | -6.04% |
| 2013 | 32.88 Billion KRW | 12.29% |
| 2012 | 29.28 Billion KRW | 15.22% |
| 2011 | 25.41 Billion KRW | -0.71% |
| 2010 | 25.59 Billion KRW | 11.68% |
| 2009 | 22.91 Billion KRW | 8.99% |
| 2008 | 21.02 Billion KRW | 7.94% |
| 2007 | 19.48 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 66.12 Billion KRW | 3.01% |
| 2024 Q1 | 64.19 Billion KRW | 3.56% |
| 2023 Q1 | 52.19 Billion KRW | 7.7% |
| 2023 Q3 | 62.29 Billion KRW | 8.06% |
| 2023 Q2 | 57.64 Billion KRW | 10.44% |
| 2023 FY | 61.98 Billion KRW | 27.9% |
| 2023 Q4 | 61.98 Billion KRW | -0.49% |
| 2022 Q1 | 42.4 Billion KRW | 6.94% |
| 2022 Q2 | 49.56 Billion KRW | 16.89% |
| 2022 Q3 | 51.31 Billion KRW | 3.53% |
| 2022 Q4 | 48.46 Billion KRW | -5.56% |
| 2022 FY | 48.46 Billion KRW | 22.22% |
| 2021 FY | 39.65 Billion KRW | -22.91% |
| 2021 Q1 | 52.98 Billion KRW | 3.01% |
| 2021 Q2 | 49.6 Billion KRW | -6.38% |
| 2021 Q3 | 43.57 Billion KRW | -12.15% |
| 2021 Q4 | 39.65 Billion KRW | -9.01% |
| 2020 Q3 | 61.31 Billion KRW | -1.69% |
| 2020 Q2 | 62.37 Billion KRW | 5.36% |
| 2020 Q1 | 59.19 Billion KRW | 5.79% |
| 2020 FY | 51.43 Billion KRW | -8.08% |
| 2020 Q4 | 51.43 Billion KRW | -16.12% |
| 2019 Q2 | 53.36 Billion KRW | 3.27% |
| 2019 Q3 | 51.81 Billion KRW | -2.9% |
| 2019 Q4 | 55.95 Billion KRW | 7.98% |
| 2019 FY | 55.95 Billion KRW | 16.98% |
| 2019 Q1 | 51.68 Billion KRW | 8.04% |
| 2018 Q2 | 43.41 Billion KRW | 11.69% |
| 2018 Q4 | 47.83 Billion KRW | 4.47% |
| 2018 FY | 47.83 Billion KRW | 17.56% |
| 2018 Q1 | 38.87 Billion KRW | -4.46% |
| 2018 Q3 | 45.78 Billion KRW | 5.45% |
| 2017 Q3 | 46.01 Billion KRW | 3.68% |
| 2017 Q4 | 40.68 Billion KRW | -11.57% |
| 2017 FY | 40.68 Billion KRW | -7.78% |
| 2017 Q1 | 44.56 Billion KRW | 1.01% |
| 2017 Q2 | 44.37 Billion KRW | -0.42% |
| 2016 Q4 | 44.11 Billion KRW | 5.56% |
| 2016 FY | 44.11 Billion KRW | 33.27% |
| 2016 Q3 | 41.79 Billion KRW | 8.06% |
| 2016 Q2 | 38.67 Billion KRW | 11.77% |
| 2016 Q1 | 34.6 Billion KRW | 4.53% |
| 2015 Q2 | 33.16 Billion KRW | 6.46% |
| 2015 Q4 | 33.1 Billion KRW | 0.29% |
| 2015 Q3 | 33.01 Billion KRW | -0.47% |
| 2015 Q1 | 31.15 Billion KRW | 0.83% |
| 2015 FY | 33.1 Billion KRW | 7.15% |
| 2014 Q1 | 33.51 Billion KRW | 1.93% |
| 2014 Q2 | 32.62 Billion KRW | -2.64% |
| 2014 FY | 30.89 Billion KRW | -6.04% |
| 2014 Q4 | 30.89 Billion KRW | -10.99% |
| 2014 Q3 | 34.71 Billion KRW | 6.38% |
| 2013 Q3 | 35.06 Billion KRW | 3.26% |
| 2013 Q4 | 32.88 Billion KRW | -6.22% |
| 2013 Q2 | 33.95 Billion KRW | 15.9% |
| 2013 FY | 32.88 Billion KRW | 12.29% |
| 2013 Q1 | 29.29 Billion KRW | 0.06% |
| 2012 FY | 29.28 Billion KRW | 15.22% |
| 2012 Q4 | 29.28 Billion KRW | 1.73% |
| 2012 Q3 | 28.78 Billion KRW | 8.09% |
| 2012 Q2 | 26.62 Billion KRW | 0.85% |
| 2012 Q1 | 26.4 Billion KRW | 3.89% |
| 2011 FY | 25.41 Billion KRW | -0.71% |
| 2011 Q2 | 20.82 Billion KRW | -5.64% |
| 2011 Q1 | 22.06 Billion KRW | -13.78% |
| 2011 Q4 | 25.41 Billion KRW | 18.11% |
| 2011 Q3 | 21.51 Billion KRW | 3.32% |
| 2010 Q1 | 22.78 Billion KRW | -0.58% |
| 2010 Q4 | 25.59 Billion KRW | 13.81% |
| 2010 Q3 | 22.48 Billion KRW | 5.12% |
| 2010 Q2 | 21.39 Billion KRW | -6.1% |
| 2010 FY | 25.59 Billion KRW | 11.68% |
| 2009 Q1 | 23.21 Billion KRW | 10.38% |
| 2009 Q4 | 22.91 Billion KRW | 17.85% |
| 2009 FY | 22.91 Billion KRW | 8.99% |
| 2009 Q2 | 20.21 Billion KRW | -12.93% |
| 2009 Q3 | 19.44 Billion KRW | -3.78% |
| 2008 Q2 | 17.55 Billion KRW | 6.57% |
| 2008 Q4 | 21.02 Billion KRW | 12.07% |
| 2008 FY | 21.02 Billion KRW | 7.94% |
| 2008 Q3 | 18.76 Billion KRW | 6.88% |
| 2008 Q1 | 16.47 Billion KRW | -15.43% |
| 2007 Q1 | 27.35 Billion KRW | 0.0% |
| 2007 Q4 | 19.48 Billion KRW | -18.39% |
| 2007 Q3 | 23.86 Billion KRW | 8.12% |
| 2007 Q2 | 22.07 Billion KRW | -19.3% |
| 2007 FY | 19.48 Billion KRW | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -40.393% |
| Dong-A Socio Holdings Co., Ltd. | 117.85 Billion KRW | 47.403% |
| Ildong Holdings Co., Ltd. | 91.16 Billion KRW | 32.007% |
| HANDOK Inc. | 94.46 Billion KRW | 34.381% |
| Kukje Pharma Co., Ltd. | 21.24 Billion KRW | -191.796% |
| Yuhan Corporation | 284.75 Billion KRW | 78.232% |
| Dong-A ST Co., Ltd. | 116.31 Billion KRW | 46.707% |
| SAMSUNG PHARM. Co., LTD. | 16.25 Billion KRW | -281.252% |
| Hanmi Pharm. Co., Ltd. | 288.81 Billion KRW | 78.538% |
| Hanall Biopharma Co.,Ltd | 32.38 Billion KRW | -91.41% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | -0.424% |
| Dong Sung Bio Pharm.Co.,Ltd. | 19.47 Billion KRW | -218.254% |
| MYUNGMOON Pharm co.,Ltd | 30.28 Billion KRW | -104.71% |
| Hana Pharm Co., Ltd. | 48.34 Billion KRW | -28.211% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -40.393% |
| Ilsung Pharmaceuticals Co., Ltd. | 31.24 Billion KRW | -98.416% |
| REYON Pharmaceutical Co., Ltd. | 35.17 Billion KRW | -76.216% |
| Aprogen pharmaceuticals,Inc. | 48.12 Billion KRW | -28.795% |
| JW Holdings Corporation | 147.58 Billion KRW | 58.001% |
| Ildong Pharmaceutical Co., Ltd. | 84.62 Billion KRW | 26.75% |
| Chong Kun Dang Pharmaceutical Corp. | 261.43 Billion KRW | 76.29% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 41.572% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -14.953% |
| Hyundai Pharmaceutical Co., Ltd. | 26.99 Billion KRW | -129.597% |
| Samil Pharmaceutical Co.,Ltd | 32.51 Billion KRW | -90.661% |
| Jeil Pharmaceutical Co.,Ltd | 109.76 Billion KRW | 43.529% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -40.393% |
| Kwang Dong Pharmaceutical Co., Ltd. | 188.64 Billion KRW | 67.141% |
| Daewoong pharmaceutical Co.,Ltd | 241.54 Billion KRW | 74.337% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 41.572% |
| Yuhan Corporation | 284.75 Billion KRW | 78.232% |
| Jeil Pharma Holdings Inc | 125.28 Billion KRW | 50.522% |
| Suheung Co., Ltd. | 259.84 Billion KRW | 76.144% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 41.572% |
| Samjin Pharmaceuticals Co., Ltd. | 79.6 Billion KRW | 22.13% |
| Korea United Pharm Inc. | 49.14 Billion KRW | -26.138% |
| CKD Bio Corp. | 69.08 Billion KRW | 10.271% |
| Daewon Pharmaceutical Co., Ltd. | 105.07 Billion KRW | 41.009% |
| Dongwha Pharm.Co.,Ltd | 70.69 Billion KRW | 12.321% |
| Whan In Pharm Co.,Ltd. | 54.05 Billion KRW | -14.667% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -14.953% |
| Chong Kun Dang Holdings Corp. | 194.76 Billion KRW | 68.174% |
| Boryung Corporation | 189.8 Billion KRW | 67.342% |
| Bukwang Pharmaceutical Co., Ltd. | 56.83 Billion KRW | -9.07% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | -0.424% |
| JW Lifescience Corporation | 23.39 Billion KRW | -164.916% |